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The prevalence of type 2 diabetes mellitus has doubled over the past 3 decades and is likely to affect a half a billion 
people in the next 3 decades.1 Given that new medications for 
diabetes mellitus could potentially be given to some tens of 
millions of people, it is vital that these medications are safe, 
and in particular, not associated with an increased vascular 
risk.2,3 The sodium glucose co-transporter 2 (SGLT2) inhibi-
tors have recently emerged as important new treatments for 
Background and Purpose—This study reports the detailed effects of canagliflozin on stroke, stroke subtypes, and vascular 
outcomes in participants with and without cerebrovascular disease (stroke or transient ischemic attack) at baseline from 
the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program.
Methods—The CANVAS Program, comprising 2 similarly designed and conducted clinical trials, randomly assigned 
10 142 participants with type 2 diabetes mellitus and high cardiovascular risk to canagliflozin or placebo. Its primary 
outcome was a composite of major adverse cardiovascular events. The main outcome of interest for this report was 
fatal or nonfatal stroke. Additional exploratory outcomes were stroke subtypes and other vascular outcomes defined 
according to standard criteria.
Results—There were 1 958 (19%) participants with prior stroke or transient ischemic attack at baseline. These individuals 
were older, more frequently women, and had higher rates of heart failure, atrial fibrillation, and microvascular disease 
(all P<0.001) compared with those without such a history. There were 309 participants with stroke events during follow-
up (123 had prior stroke or transient ischemic attack at baseline and 186 did not), at a rate of 7.93/1000 patient-years 
among those assigned canagliflozin and 9.62/1000 patient-years among placebo (hazard ratio, 0.87; 95% CI, 0.69–
1.09). Analysis of stroke subtypes found no effect on ischemic stroke (n=253, hazard ratio, 0.95; 95% CI, 0.74–1.22), a 
significant reduction for hemorrhagic stroke (n=30, hazard ratio, 0.43; 95% CI, 0.20–0.89) and no effect on undetermined 
stroke (n=29, hazard ratio, 1.04; 95% CI, 0.48–2.22). Effects on other cardiovascular outcomes were comparable among 
participants with and without stroke or transient ischemic attack at baseline.
Conclusions—There were too few events in the CANVAS Program to separately define the effects of canagliflozin on 
stroke, but benefit is more likely than harm. The observed possible protective effect for hemorrhagic stroke was based on 
small numbers but warrants further investigation.
Clinical Trial Registration—URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754.  
(Stroke. 2019;50:396-404. DOI: 10.1161/STROKEAHA.118.023009.)
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diabetes mellitus. The mechanism of action, by reducing the 
reuptake of glucose in the kidney, lowers blood glucose, with 
other favorable effects on biomarkers, particularly weight 
loss.4 Evidence of the effect of SGLT2 inhibitors on vas-
cular events has come from 2 trial programs, the EMPA-REG 
OUTCOME trial (Empagliflozin Cardiovascular Outcome 
Event Trial in Type 2 Diabetes Mellitus Patients) testing empa-
gliflozin5 and the CANVAS (Canagliflozin Cardiovascular 
Assessment Study) Program trials testing canagliflozin.6 In 
the EMPA-REG OUTCOME study, there was a nonsignifi-
cant increase in the risk of stroke (hazard ratio [HR], 1.18; 
95% CI, 0.89–1.56), and in the CANVAS Program, there was 
a nonsignificant decrease in the risk of stroke (HR, 0.87; 95% 
CI, 0.69–1.09). Extensive subsidiary analyses of EMPA-REG 
OUTCOME have not identified any adverse effect of empa-
gliflozin that might have caused an increase in stroke risk.7 
Given that type 2 diabetes mellitus is associated with an ap-
proximate doubling in the risk of stroke compared with people 
without diabetes mellitus,8 it is important to understand more 
about the effects of these drugs on stroke and whether those 
with established cerebrovascular disease have any additional 
risks or benefits compared with those without. The aim of this 
study was to explore the detailed effects of canagliflozin on 
stroke, stroke subtypes, and other vascular outcomes among 
CANVAS Program participants and to analyze whether these 
effects differed for those with and without a history of cere-




The study design, characteristics of participants, and the main 
results of the CANVAS Program have previously been pub-
lished.6,9–11 In brief, the CANVAS Program, comprising 2 simi-
larly designed and conducted trials—CANVAS and CANVAS-R 
(CANVAS-Renal)—was designed to assess the cardiovascular and 
renal safety and efficacy of canagliflozin, and how any potential 
benefits might balance against risks. There were 667 centers in 30 
countries in the 2 trials that were scheduled for joint close-out and 
analysis when at least 688 cardiovascular events and a minimum of 
78 weeks follow-up had been accrued for the last randomized par-
ticipant, which occurred in February 2017.
Data from the CANVAS Program will be made available in the 
public domain via the Yale University Open Data Access Project 
(YODA; http://yoda.yale.edu/) once the product and relevant indica-
tion studied have been approved by regulators in the United States 
and European Union and the study has been completed for 18 months. 
The trial protocols and statistical analysis plans were published along 
with the primary CANVAS Program manuscript.6
Participants
Participants in the CANVAS Program were those with type 2 dia-
betes mellitus (glycated hemoglobin [HbA1c] ≥7.0% and ≤10.5%), 
aged ≥30 years with a history of symptomatic atherosclerotic car-
diovascular disease, or ≥50 years with ≥2 risk factors for cardio-
vascular disease (duration of diabetes mellitus ≥10 years, systolic 
blood pressure [BP] >140 mmHg while on one or more antihyper-
tensive agents, current smoker, microalbuminuria or macroalbumin-
uria, or high-density lipoprotein-cholesterol [HDL-C] <1 mmol/L). 
Patients treated with insulin and those with mild to moderate renal 
failure (estimated glomerular filtration rate [eGFR] ≥30 mL/min 
per 1.73 m2) were included. For the analyses presented in this re-
port, a baseline diagnosis of cerebrovascular disease was based on a 
self-report of prior stroke or TIA.
Randomization, Treatment, and Follow-Up
After a 2-week, single-blind, placebo run-in period, participants were 
randomized centrally through an interactive web response system 
using a computer-generated randomization schedule prepared by 
the study sponsor using randomly permuted blocks. Participants in 
CANVAS were assigned in a 1:1:1 ratio to canagliflozin 300 mg, 
canagliflozin 100 mg, or matching placebo, and participants in 
CANVAS-R were randomly assigned in a 1:1 ratio to canagliflozin 
or matching placebo, administered at an initial dose of 100 mg daily 
with optional uptitration to 300 mg from week 13. Participants and 
all study staff were masked to individual treatment allocations until 
HR (95% CI)





Undetermined 29 1.04 (0.48, 2.22)
Fatal 39 0.84 (0.44, 1.59)
Nonfatal 274 0.90 (0.71, 1.15)
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Participants with an event 
per 1000 patient-years
Figure 1. Effects of canagliflozin on stroke and TIA. *TIAs were not adjudicated but based upon adverse event reports made by site investigators. Incomplete 
ascertainment of TIAs is possible because adverse event reporting in the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program was stream-
lined from January 2014 to capture only serious adverse events and adverse events leading to discontinuation, and TIA events considered by the site investi-
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the completion of the study. Use of other background therapy for gly-
cemic management, prevention of stroke and other cardiovascular 
outcomes, and other diseases was according to best practice instituted 
in line with local guidelines.
Participants were followed after randomization in a face-to-
face follow-up that was scheduled for 3 visits in the first year and 
at 6-month intervals thereafter, with alternating telephone follow-up 
between face-to-face assessments. Every follow-up included inquiry 
about primary and secondary outcome events and serious adverse 
events. Serum creatinine measurement with eGFR was performed at 
least every 26 weeks in both trials. Participants who prematurely dis-
continued study treatment continued scheduled follow-up wherever 
possible, with extensive efforts made to obtain full outcome data for 
all during the final follow-up window that spanned from November 
2016 to February 2017.
Outcomes
The main outcome of interest for this report is fatal or nonfatal stroke. 
These were originally part of the primary composite outcome of 
major adverse cardiovascular events (nonfatal stroke, nonfatal my-
ocardial infarction, or cardiovascular death) used for the CANVAS 
Program.6 Additional exploratory outcomes for this report were fatal 
stroke; nonfatal stroke; ischemic stroke, hemorrhagic stroke, and 
stroke of undetermined type; TIA; stroke or TIA; major adverse car-
diovascular events (nonfatal stroke, nonfatal myocardial infarction, 
or cardiovascular death); fatal or nonfatal myocardial infarction; 
hospitalized heart failure; cardiovascular death; all-cause mortality; 
progression of albuminuria (defined as >30% increase in albuminuria 
and a change from either normoalbuminuria to microalbuminuria or 
macroalbuminuria or from microalbuminuria to macroalbuminuria); 
and serious decline in kidney function (defined as a 40% reduction in 
eGFR sustained for at least 2 consecutive measures, end-stage kidney 
disease, or death from renal causes). Possible intermediate markers of 
stroke risk were also analyzed, which included systolic BP, diastolic 
BP, body weight, HbA1c, cholesterol, triglycerides, hematocrit, uri-
nary albumin-to-creatinine ratio, eGFR, and adverse events of atrial 
fibrillation reported during follow-up.
Endpoint Adjudication Committees (online-only Data Supplement) 
adjudicated all cardiovascular outcomes, renal outcomes, and deaths, 
with stroke events adjudicated by experienced stroke physicians 
(online-only Data Supplement). Stroke was defined using the 2013 
American Heart Association/American Stroke Association criteria.12 
Ischemic and hemorrhagic stroke were determined by the neuroim-
aging findings, while undetermined stroke represented a clinical 
stroke without acute imaging to confirm the cause. TIAs were de-
fined as a transient impairment of neurological function lasting <24 
hours and without evidence of stroke on any acute neuroimaging. The 
Endpoint Adjudication Committee reviewed all suspected strokes and 
transient neurological events (including TIAs) as originally reported 
by the site investigators to determine whether the event met the criteria 
for a stroke. A reported TIA event could be adjudicated as a stroke 
event and it was removed from the analysis of TIA events if this was 
the case. Therefore, TIA events included in the analyses within this 
report were those not adjudicated to be stroke events.
Statistical Analysis
Categorical variables were summarized as the number of patients 
(with corresponding percentages), and continuous variables were 
summarized as the mean and SD or the median and interquartile 
range. Differences in baseline characteristics between participants 
with a history of cerebrovascular disease compared with participants 
with no history of cerebrovascular disease were evaluated using gen-
eralized Cochran-Mantel-Haenszel test, ANOVA, or the Wilcoxon 
rank-sum test. Efficacy analyses were based upon the full, integrated 
dataset and the intent-to-treat approach, with the comparison being 
between all participants assigned to canagliflozin (regardless of dose) 
and all participants assigned to placebo. Analyses were based on 
the occurrence of the first event under investigation. The trial was 
powered to detect an effect on the primary composite outcome and 
not for the analyses of stroke. Annualized incidence rates per 1000 
patient-years of follow-up were calculated for all outcomes in addi-
tion to HRs and 95% CIs determined from Cox regression models, 
with treatment as the exploratory variable, and factors of trial and 
history of cardiovascular disease included in the model. We tested 
the homogeneity of treatment effects across the 2 contributing trials 
using P values for interactions, and the same approach was used for 
testing comparability of effects across subgroups defined by base-
line participant characteristics. Sensitivity analyses of fatal or nonfa-
tal stroke were performed according to whether the events occurred 
on-treatment or within 7, 30, or 90 days of treatment discontinua-
tion. Effects of canagliflozin on continuous intermediate markers of 
stroke risk were analyzed using an ANCOVA model with treatment 
Figure 2. Effects of canagliflozin on fatal and nonfatal stroke. A, Fatal or 
nonfatal stroke. B, Nonfatal stroke. Reprinted from Neal et al6 with permis-
sion. Copyright ©2017, Massachusetts Medical Society. C, Fatal stroke. 
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as an independent effect and adjusting for trial and baseline value. 
Change in the continuous intermediate marker from baseline to the 
last measurement throughout the trials and the difference of cana-
gliflozin compared with placebo in the least squares means were esti-
mated from the model. For atrial fibrillation, the HR with 95% CI 
was estimated from the same Cox regression model that was used 
to determine effects on stroke. Analyses were performed using SAS 
Enterprise Guide version 7.1.
Standard Protocol Approvals, 
Registrations, and Patient Consents
The protocols for the 2 trials were approved by the ethics committees 
at each site. All participants provided written informed consent.
Results
There were 10 142 patients in the CANVAS Program (Figure I 
in the online-only Data Supplement), and the mean follow-up 
time was 188.2 weeks. Mean age was 63.3 years, 35.8% were 
women, mean duration of diabetes mellitus was 13.5 years, 
and 65.6% had a history of cardiovascular disease. A total of 
1 958 (19.3%) participants reported a history of cerebrovas-
cular disease (stroke or TIA) at baseline. These participants 
were significantly different from other trial participants in 
most aspects of demography, disease history, and medica-
tion for the management of stroke risks, though the absolute 
magnitude of the differences was mostly small (Table I in the 
online-only Data Supplement). Atrial fibrillation was reported 
at baseline in 8.6% of those with cerebrovascular disease com-
pared with 5.4% among those without.
Effects of Canagliflozin on Stroke, 
TIA, and Stroke Subtypes
There were 309 trial participants with a fatal or nonfatal stroke 
recorded during follow-up (123 had prior stroke or TIA at 
baseline and 186 did not), at a rate of 7.93/1000 patient-years 
Table 1. Effects of Canagliflozin on Possible Intermediate Markers of Stroke Risk
Change From Baseline to the Last Measurement*
Mean Treatment
 Difference (95% CI)† P ValueCanagliflozin Placebo
Systolic BP, mmHg −4.86 (0.19) −1.73 (0.22) −3.14 (−3.71, −2.57) <0.001
Diastolic BP, mmHg −3.21 (0.11) −2.39 (0.13) −0.82 (−1.15, −0.48) <0.001
Body weight, kg −3.21 (0.08) −0.81 (0.09) −2.40 (−2.64, −2.17) <0.001
HbA1c, % −0.42 (0.02) −0.03 (0.02) −0.39 (−0.44, −0.34) <0.001
HDL-C, mmol/L 0.04 (0.00) −0.01 (0.00) 0.05 (0.04, 0.06) <0.001
LDL-C, mmol/L 0.08 (0.01) −0.03 (0.01) 0.12 (0.08, 0.15) <0.001
Ratio of LDL-C to HDL-C, % 0.32 (1.09) −0.70 (1.31) 1.02 (−2.33, 4.36) 0.55
Triglycerides, mmol/L 0.08 (0.02) 0.02 (0.02) 0.06 (0.00, 0.11) 0.04
Total cholesterol, mmol/L 0.14 (0.01) −0.04 (0.02) 0.18 (0.14, 0.22) <0.001
Hematocrit, % 1.63 (0.05) −0.90 (0.06) 2.53 (2.38, 2.68) <0.001
Albumin:creatinine ratio, mg/g 21.01 (6.30) 84.55 (7.49) −63.55 (−82.73, −44.36) <0.001
eGFR, mL/min per 1.73 m2 −1.82 (0.19) −3.87 (0.23) 2.05 (1.47, 2.62) <0.001
BP indicates blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein-cholesterol; HR, hazard ratio; 
and LDL-C, low-density lipoprotein-cholesterol.
*Change from baseline to the last measurement was analyzed for participants with both baseline and at least 1 post-baseline measurement using an ANCOVA model 
with treatment as an independent effect and adjusting for trial and baseline value. Data are the change of least squares means (SE).
†The mean treatment difference of canagliflozin compared with placebo in the least squares means and associated 95% CIs were estimated from the model.
Table 2. Effects of Canagliflozin on Atrial Fibrillation
 
Canagliflozin Placebo
HR* (95% CI) P InteractionEvents, n
Participants With an 
Event per 1000 pt-yr Events, n
Participants With an 
Event per 1000 pt-yr
Reported AF† 125 5.64 84 6.08 0.84 (0.64, 1.12) 0.99
  Without AF history‡ 100 4.75 67 5.11 0.82 (0.60, 1.11)
  With AF history§ 25 21.90 17 23.37 0.93 (0.50, 1.74)
AF indicates atrial fibrillation; HR, hazard ratio; and pt-yr, patient-years.
*HRs and 95% CIs are determined from Cox regression models, with treatment as the exploratory variable and stratification according to trial and history of 
cardiovascular disease.
†AF events were identified from site investigator–reported adverse events.
‡AF events occurred during follow-up in participants without AF history.
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among those assigned canagliflozin and 9.62/1000 patient-
years among those assigned placebo (HR, 0.87; 95% CI, 0.69–
1.09; Figures 1 and 2). Hemorrhagic stroke was uncommon 
(30 events), with an observed reduction in risk for those allo-
cated to canagliflozin compared with placebo (HR, 0.43; 95% 
CI, 0.20–0.89; Figures 1 and 3). The rate of ischemic stroke 
was also lower among those treated with canagliflozin com-
pared with placebo (n=253; HR, 0.95; 95% CI, 0.74–1.22), 
but this did not reach statistical significance. The rate of un-
determined stroke events (n=29) was similar in both groups 
(HR, 1.04; 95% CI, 0.48–2.22). Point estimates of effect were 
consistent and below unity for fatal stroke (n=39; HR, 0.84; 
95% CI, 0.44–1.59), nonfatal stroke (n=274; HR, 0.90; 95% 
CI, 0.71–1.15), TIA (n=88; HR, 0.86; 95% CI, 0.56–1.32), 
and the composite of stroke or TIA (n=377; HR, 0.89; 95% 
CI, 0.73–1.10), but none of these individual results were sta-
tistically significant. The estimate of effect of canagliflozin 
on stroke risk did not vary with the time since the last dose 
of randomized treatment (Figure II in the online-only Data 
Supplement). The use of antithrombotic agents at baseline had 
no effect on the risk of hemorrhagic stroke (HR, 0.63; 95% CI, 
0.22–1.76).
Effects on Possible Intermediate 
Markers of Stroke Risk
There were favorable effects of canagliflozin compared with 
placebo on systolic BP, diastolic BP, body weight, HbA1c, 
HDL-C, urinary albumin-to-creatinine ratio, and eGFR. Small 
increases were observed for hematocrit, low-density lipopro-
tein-cholesterol (LDL-C), total cholesterol, and triglycerides 
with null effects on the ratio of HDL-C to LDL-C (Table 1). 
There was no detectable effect of canagliflozin compared 
with placebo on atrial fibrillation (HR, 0.84; 95% CI, 0.64–
1.12), which was also true for the subsets of participants with 
and without atrial fibrillation history at baseline (P interac-
tion=0.99; Table 2).
Effects of Canagliflozin on Stroke 
in Patient Subgroups
Effects of treatment on stroke were similar in CANVAS 
and CANVAS-R (HR, 0.93; 95% CI, 0.69–1.27 versus HR, 
0.80; 95% CI, 0.56–1.13; P interaction=0.51) and for most 
other participant subgroups (Figure 4). The exceptions were 
subsets defined by age (P interaction=0.006), eGFR (P in-
teraction=0.005), and use of antithrombotic therapy (P in-
teraction=0.04), which indicated greater protection in older 
patients, those with lower eGFR, and those reporting anti-
thrombotic use.
Effects of Canagliflozin on Cardiovascular, 
Kidney, and Death Outcomes in Patients With and 
Without Cerebrovascular Disease at Baseline
Patients with stroke or TIA at baseline were at higher abso-
lute risk of subsequent stroke and all other vascular outcomes, 
with 123 stroke events occurring in those 1 958 patients with 
prior stroke or TIA versus 186 in the 8 184 patients without. 
The proportional effects of canagliflozin compared with pla-
cebo were comparable in patients with and without cerebro-
vascular disease at baseline for cardiovascular, kidney, and 
death outcomes (all P interaction >0.19; Figure 5).
Discussion
In the CANVAS Program, the composite of nonfatal stroke, 
nonfatal myocardial infarction, and cardiovascular death was 
significantly reduced, with a favorable (but not statistically 
significant) reduction in each of the 3 components.6 Similarly, 
in these analyses, our primary outcome of stroke (fatal or 
nonfatal), although with a favorable point estimate of effect, 
was not statistically significant. The CANVAS Program was 
not powered to examine the individual contributions of stroke, 
Figure 3. Effects of canagliflozin on stroke subtypes. A, Ischemic stroke. 
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myocardial infarction, and cardiovascular death to the pri-
mary outcome, but the observed effect on stroke events is con-
sistent with that initially anticipated on the basis of the known 
BP-lowering effect of the compound.13 Analysis according to 
pathological stroke subtype identified separately statistically 
significant protection against hemorrhagic stroke, albeit with 
small numbers, though there was no clear effect on ischemic 
stroke or undetermined stroke. The hemorrhagic stroke result, 
if confirmed, could be consistent with a BP-lowering mech-
anism of stroke prevention with canagliflozin, at least in part, 
as hemorrhagic stroke is more strongly determined by higher 
BP than ischemic stroke.13
Favors placeboFavors canagliflozin
Study
CANVAS 7.34 7.86 0.93 (0.69, 1.27) 0.51
CANVAS-R 9.55 11.96 0.80 (0.56, 1.13)
Age
<65 years 7.40 6.28 1.17 (0.83, 1.65) 0.006
≥65 years 8.67 14.15 0.68 (0.50, 0.93)
Gender
Male 8.26 11.11 0.79 (0.60, 1.04) 0.14
Female 7.32 6.92 1.09 (0.71, 1.69)
Race
White 8.63 10.88 0.82 (0.64, 1.05) 0.71
Black 7.31 10.43 0.75 (0.18, 3.11)
Asian 5.09 4.02 1.54 (0.66, 3.58)
Other 6.97 6.35 1.13 (0.37, 3.43)
Region
North America 6.53 7.10 0.93 (0.55, 1.56) 0.08
Central and South America 8.84 5.40 1.80 (0.67, 4.82)
Europe 7.24 12.63 0.58 (0.40, 0.85)
Rest of the world 9.59 9.39 1.13 (0.77, 1.66)
BMI
<30 kg/m2 6.70 10.18 0.74 (0.51, 1.06) 0.12
≥30 kg/m2 8.79 9.14 0.98 (0.73, 1.32)
BP control
SBP ≥140 mmHg or DBP ≥90 mmHg 8.39 10.12 0.91 (0.65, 1.27) 0.95
SBP <140 mmHg and DBP <90 mmHg 7.59 9.21 0.85 (0.62, 1.16)
Duration of diabetes mellitus
≥10 years 7.16 9.43 0.81 (0.61, 1.08) 0.41
<10 years 9.76 10.09 1.00 (0.67, 1.48)
HbA1c
<8% 7.20 9.48 0.84 (0.59, 1.19) 0.56
≥8% 8.53 9.74 0.89 (0.66, 1.21)
eGFR
30 to <60 mL/min per 1.73 m2 6.66 14.52 0.50 (0.30, 0.83) 0.005
60 to <90 mL/min per 1.73 m2 7.69 9.32 0.89 (0.65, 1.21)
≥90 mL/min per 1.73 m2 9.47 6.62 1.42 (0.86, 2.36)
Yes 9.53 12.19 0.82 (0.63, 1.06) 0.36
No 5.44 5.38 1.06 (0.66, 1.71)
History of cerebrovascular disease
Yes 18.29 21.31 0.88 (0.61, 1.26) 0.85
No 5.74 7.12 0.84 (0.63, 1.13)
History of PVD
Yes 9.14 10.89 0.88 (0.53, 1.45) 0.90
No 7.67 9.33 0.87 (0.67, 1.12)
History of atrial fibrillation
Yes 10.98 21.35 0.57 (0.27, 1.19) 0.16
No 7.76 8.95 0.91 (0.71, 1.16)
History of heart failure
Yes 11.98 15.87 0.84 (0.51, 1.38) 0.57
No 7.36 8.63 0.88 (0.68, 1.14)
History of amputation
Yes 8.28 16.65 0.62 (0.14, 2.68) 0.58
No 7.93 9.50 0.88 (0.70, 1.11)
Insulin use
Yes 9.21 10.96 0.88 (0.65, 1.19) 0.87
No 6.69 8.28 0.86 (0.60, 1.22)
Statin use
Yes 7.59 9.24 0.89 (0.68, 1.17) 0.95
No 8.93 10.75 0.83 (0.54, 1.28)
Antithrombotic use
Yes 8.18 11.12 0.79 (0.61, 1.02) 0.04
No 7.29 5.46 1.32 (0.78, 2.26)
RAAS inhibitor use
Yes 8.45 9.28 0.96 (0.74, 1.23) 0.07
No 5.87 11.03 0.57 (0.33, 0.97)
Beta-blocker use
Yes 7.44 10.17 0.79 (0.57, 1.08) 0.25
No 8.46 9.01 0.97 (0.70, 1.36)
Diuretic use
Yes 6.69 10.40 0.69 (0.48, 0.98) 0.06
No 8.90 9.00 1.03 (0.76, 1.40)
1.00.50.25 2.0 4.0
Canagliflozin Placebo HR (95% CI) P value
History of CV disease
Participants with an event 
per 1000 patient-years
Figure 4. Effects of canagliflozin on stroke in patient subgroups. BMI indicates body mass index; BP, blood pressure; CANVAS, Canagliflozin Cardiovascular 
Assessment Study; CANVAS-R, CANVAS-Renal; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, gly-
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Stroke, in particular, but also most other cardiovascular 
outcomes and death, occurred more frequently in patients 
with a baseline history of stroke or TIA compared with those 
without, though both sets of participants experienced compa-
rable proportional reductions in the risks of these outcomes 
with use of canagliflozin.14
The effects of canagliflozin were broadly similar across 
a wide range of other participants, such as those using es-
tablished treatments for the prevention of stroke, such as 
BP-lowering therapy, and patients of different ethnic back-
grounds. The borderline significant interaction of cana-
gliflozin treatment and stroke prevention with baseline use 
of an antithrombotic is likely to reflect a chance finding con-
sequent upon the many comparisons made rather than a real 
effect. There was no corresponding evidence of an interac-
tion by use of acetylsalicylic acid or anticoagulant therapy for 
stroke in EMPA-REG OUTCOME, though those participants 
all had a baseline history of cardiovascular disease and base-
line use of these agents was greater.7 By contrast, the signifi-
cance level of the interactions of canagliflozin and stroke with 
age and eGFR make chance a less likely explanation, though 
the strong correlation between age and lower eGFR mean that 
these observations may not be independent of one another. A 
biological explanation for a greater effect of canagliflozin on 
stroke reduction in older compared with younger individu-
als or among individuals with impaired compared with pre-
served renal function is unknown, though comparable trends 
were noted in EMPA-REG OUTCOME.7 The CREDENCE 
trial (Canagliflozin and Renal Endpoints in Diabetes With 
Established Nephropathy Clinical Evaluation), which was 
done in patients with impaired renal function, will provide 
significant additional insight into these effects and may pro-
vide an indication of mechanism.15
Beneficial effects of canagliflozin on stroke might 
be anticipated based upon the BP lowering achieved with 
SGLT2 inhibition, since BP reduction is well known to sig-
nificantly reduce both first and recurrent stroke, with greater 
reduction for hemorrhagic stroke.16–20 Theoretical risks of 
hypoperfusion attributable to hypovolemia or hypotension21 
have not been observed in prior large trials of stroke pre-
vention, and there was no evidence for such effects in the 
CANVAS Program. Hemorrhagic stroke is especially BP 
dependent,13 so while the positive effect on this outcome 
observed in the CANVAS Program was based on relatively 
few events, a positive finding for hemorrhagic stroke is con-
sistent with stroke epidemiology and clinical trials, albeit 
larger in magnitude than might have been expected for the 
observed BP reduction. Potential mechanisms for BP lower-
ing with SGLT2 inhibition include natriuresis, osmotic diu-
resis (leading to volume depletion), and reduction in body 
weight.22 The changes in lipid parameters with canagliflozin 
would tend to favor hemorrhagic stroke prevention, though 
effects on cholesterol were small. Additional anti-atheroscle-
rotic effects of SGLT2 inhibition mediated through effects 
on glucose and obesity may also contribute to protection 
against stroke in the longer term.23 There was no evidence 
of an adverse effect mediated through hemoconcentration, 
with favorable directions of effect for strokes of ischemic 
as well as hemorrhagic origin. Likewise, there was no ev-
idence of any adverse effect of withdrawal of randomized 
treatment on stroke risk,7 with constant HRs observed for 
strokes occurring on-treatment and at various intervals after 
treatment discontinuation.
The findings reported here are strengthened by the rig-
orous design and conduct of the trial, the prespecification of 
stroke as an outcome of interest, and the careful adjudication 
Favors placeboFavors canagliflozin






















Serious decline in kidney function*
Without cerebrovascular disease
With cerebrovascular disease
23.5 28.6 0.82 (0.70, 0.95) 0.41
43.0 45.0 0.96 (0.75, 1.23)
5.7 7.1 0.84 (0.63, 1.13) 0.85
18.3 21.3 0.88 (0.61, 1.26)
10.8 13.0 0.83 (0.67, 1.03) 0.19
13.3 10.9 1.24 (0.77, 1.99)
10.3 11.7 0.84 (0.68, 1.05) 0.76
17.5 18.2 0.97 (0.67, 1.41)
5.1 7.6 0.71 (0.53, 0.95) 0.33
7.2 13.8 0.57 (0.34, 0.94)
16.0 18.3 0.85 (0.71, 1.01) 0.83
23.3 25.1 0.92 (0.67, 1.26)
85.1 123.9 0.72 (0.66, 0.79) 0.55
109.8 151.4 0.75 (0.62, 0.89)
5.4 8.5 0.63 (0.47, 0.83) 0.48
6.0 11.3 0.49 (0.28, 0.85)
1.00.50.25 2.0
Participants with an event 
per 1000 patient-years
Figure 5. Effects of canagliflozin on cardiovascular and renal outcomes in patient with and without cerebrovascular (stroke or TIA) disease at baseline. eGFR 
indicates estimated glomerular filtration rate; HR, hazard ratio; MACE, major adverse cardiovascular events (nonfatal stroke, nonfatal myocardial infarction, 
or cardiovascular death); and TIA, transient ischemic attack. *Composite of 40% reduction in eGFR sustained for at least 2 consecutive measures, end-stage 
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of all potential stroke events according to recognized subtypes 
by an expert committee. This included screening all events 
reported as TIA for possible stroke events by the Endpoint 
Adjudication Committee, which resulted in additional stroke 
events being identified. Our study has limitations, the chief 
one being that the study was not powered to detect signifi-
cant differences in total stroke events. The possible difference 
in effects by subtype of stroke needs to be interpreted with 
caution as a consequence but warrants further investigation. 
A further weakness is that TIAs were not themselves adju-
dicated, but all TIA events were screened by the stroke adju-
dicators to ensure stroke had not been misreported as TIA. 
Incomplete ascertainment of TIAs is possible because adverse 
event reporting in the CANVAS Program was streamlined 
from January 2014 to capture only serious adverse events and 
adverse events leading to discontinuation, and TIA events 
considered by the site investigator as nonserious would not be 
captured after this time. Missing TIA events should, however, 
be distributed nondifferentially between active and control 
groups and should not bias our results.
The unfavorable direction of effect reported for stroke in 
the EMPA-REG OUTCOME trial was not observed within 
the CANVAS Program, with a nonsignificant lower rate of all 
stroke events in those treated with canagliflozin and an indi-
cation of a possible beneficial effect for hemorrhagic stroke. 
The EMPA-REG OUTCOME trial recorded only about half 
as many hemorrhagic strokes as the CANVAS Program and 
did not report the effect of empagliflozin on that outcome, so 
comparability of the effects of the compounds on hemorrhagic 
stroke cannot be determined. Additional data from ongoing 
trials of SGLT2 inhibitors will provide further insight, and the 
CREDENCE trial, in particular, should clarify whether the 
effects of SGLT2 inhibition on stroke are enhanced in patients 
with chronic kidney disease.
Conclusions
The CANVAS Program demonstrated a reduction in the primary 
composite outcome of nonfatal stroke, nonfatal myocardial in-
farction, and cardiovascular death. There were too few events 
to separately define the effects of canagliflozin on stroke, but 
these analyses show that benefit is more likely than harm. The 
observed possible protective effect for hemorrhagic stroke was 
based on small numbers but warrants further investigation.
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